CY1106526T1 - Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης - Google Patents

Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης

Info

Publication number
CY1106526T1
CY1106526T1 CY20071100529T CY071100529T CY1106526T1 CY 1106526 T1 CY1106526 T1 CY 1106526T1 CY 20071100529 T CY20071100529 T CY 20071100529T CY 071100529 T CY071100529 T CY 071100529T CY 1106526 T1 CY1106526 T1 CY 1106526T1
Authority
CY
Cyprus
Prior art keywords
thiazol
benzamide derivatives
agonists
receptor
neurological
Prior art date
Application number
CY20071100529T
Other languages
English (en)
Inventor
Anette Graven Sams
Mogens Larsen
Gitte Mikkelsen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1106526T1 publication Critical patent/CY1106526T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση αναφέρεται σε παράγωγα Ν-θειαζολ-2-υλο-βενζαμίδης του τύπου I στην περιγραφή όπου οι μεταβλητές είναι όπως ορίζονται στις αξιώσεις. Οι ενώσεις είναι σύνδεσμοι υποδοχέα Α2α, όπως ανταγωνιστές, αγωνιστές, αντίστροφοι αγωνιστές ή μερικοί αγωνιστές, και είναι χρήσιμες στην θεραπεία νευρολογικών και ψυχιατρικών διαταραχών όπου εμπλέκεται ένας υποδοχέας Α2Α.
CY20071100529T 2003-10-27 2007-04-19 Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης CY1106526T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301579 2003-10-27
DKPA200400229 2004-02-13
PCT/DK2004/000733 WO2005039572A1 (en) 2003-10-27 2004-10-25 N-thiazol-2-yl-benzamide derivatives

Publications (1)

Publication Number Publication Date
CY1106526T1 true CY1106526T1 (el) 2012-01-25

Family

ID=34524309

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100529T CY1106526T1 (el) 2003-10-27 2007-04-19 Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης

Country Status (28)

Country Link
US (2) US20060154974A1 (el)
EP (2) EP1803455A1 (el)
JP (1) JP2007509083A (el)
KR (1) KR20060093726A (el)
AR (1) AR047621A1 (el)
AT (1) ATE354365T1 (el)
AU (1) AU2004283019A1 (el)
BR (1) BRPI0415661A (el)
CA (1) CA2542816A1 (el)
CO (1) CO5690582A2 (el)
CY (1) CY1106526T1 (el)
DE (1) DE602004004925T2 (el)
DK (1) DK1682129T3 (el)
EA (2) EA200801734A1 (el)
ES (1) ES2279414T3 (el)
HR (1) HRP20070194T3 (el)
IL (1) IL175189A0 (el)
IS (1) IS8364A (el)
ME (1) MEP6708A (el)
MX (1) MXPA06004436A (el)
NO (1) NO20062417L (el)
PL (1) PL1682129T3 (el)
PT (1) PT1682129E (el)
RS (1) RS20060289A (el)
SG (1) SG147472A1 (el)
SI (1) SI1682129T1 (el)
TW (1) TW200524887A (el)
WO (1) WO2005039572A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
AU2005287729A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
TW200720264A (en) * 2005-04-25 2007-06-01 Lundbeck & Co As H Pro-drugs of n-thiazol-2-yl-benzamide derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
JPWO2006137527A1 (ja) * 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
LT1921077T (lt) 2005-08-02 2017-09-25 Kyowa Hakko Kirin Co., Ltd. Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
RU2483722C1 (ru) * 2012-05-22 2013-06-10 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Аминотиазольные производные усниновой кислоты как новые противотуберкулезные агенты
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE855120C (de) * 1950-10-08 1953-01-05 Schering Ag Verfahren zur Herstellung von Aminosalicylsaeureamiden
JP2903339B2 (ja) * 1990-10-12 1999-06-07 大日精化工業株式会社 電子写真感光体
WO1998017654A1 (fr) * 1996-10-24 1998-04-30 Zeria Pharmaceutical Co., Ltd. Derives de benzoylaminothiazole substitues et medicaments les contenant
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1354880A4 (en) * 2001-01-26 2004-08-25 Shionogi & Co HALOGEN COMPOUNDS HAVING AGONISM TOWARDS THROMBOPOIETIN RECEPTOR
US7429593B2 (en) * 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives

Also Published As

Publication number Publication date
TW200524887A (en) 2005-08-01
MXPA06004436A (es) 2006-06-20
CO5690582A2 (es) 2006-10-31
KR20060093726A (ko) 2006-08-25
CA2542816A1 (en) 2005-05-06
DE602004004925T2 (de) 2007-10-31
US20060154974A1 (en) 2006-07-13
NO20062417L (no) 2006-05-26
PL1682129T3 (pl) 2007-07-31
ATE354365T1 (de) 2007-03-15
US20090247593A1 (en) 2009-10-01
IS8364A (is) 2006-03-20
AR047621A1 (es) 2006-02-01
EP1682129A1 (en) 2006-07-26
SI1682129T1 (sl) 2007-06-30
EP1803455A1 (en) 2007-07-04
PT1682129E (pt) 2007-04-30
AU2004283019A1 (en) 2005-05-06
EA200801734A1 (ru) 2008-12-30
EA200600860A1 (ru) 2006-08-25
IL175189A0 (en) 2006-09-05
EA010790B1 (ru) 2008-10-30
WO2005039572A1 (en) 2005-05-06
RS20060289A (en) 2008-06-05
BRPI0415661A (pt) 2006-12-19
EP1682129B1 (en) 2007-02-21
JP2007509083A (ja) 2007-04-12
DK1682129T3 (da) 2007-06-11
ES2279414T3 (es) 2007-08-16
SG147472A1 (en) 2008-11-28
HRP20070194T3 (en) 2007-06-30
DE602004004925D1 (de) 2007-04-05
MEP6708A (xx) 2010-02-10

Similar Documents

Publication Publication Date Title
CY1106526T1 (el) Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης
CY1105907T1 (el) Νεα παραγωγα της 1,2,4 - θειαδιαζολης ως ρυθμιστες υποδοχεως μελανοκορτινης
CY1114277T1 (el) ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
CY1107475T1 (el) Αναστολεις ρο-κινασης
CY1106894T1 (el) Παραγωγα σουλφοναμιδιων για την αγωγη ασθενειων
CY1108041T1 (el) Αναστολεις της rho-κινασης
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
CY1116104T1 (el) Μεθοδος για την παρασκευη ρυθμιστων οπιοειδους
NO20061137L (no) Cyklopropylderivater som NK3-reseptorantagonister
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
CY1112038T1 (el) Αναστολεις της κινασης τυροσινης
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6